Denali Therapeutics (4DN) Price & Analysis

Compare

7 Followers

4DN Stock Chart & Stats

€17.42

€2.53(14.09%)

At close: Jan 08 4:00 PM EST

€17.42

€2.53(14.09%)

Day’s Range― - ―

52-Week Range€10.17 - €19.24

Previous CloseN/A

Volume0.00

Average Volume (3M)31.00

Market Cap

€2.85B

Enterprise Value€2.95B

Total Cash (Recent Filing)€867.88M

Total Debt (Recent Filing)€32.74M

Price to Earnings (P/E)―

Beta0.91

Next Earnings

May 12, 2026

EPS Estimate

-0.55

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.62

Shares Outstanding158,591,490

10 Day Avg. Volume8

30 Day Avg. Volume31

Financial Highlights & Ratios

PEG Ratio-0.36

Price to Book (P/B)2.86

Price to Sales (P/S)0.00

P/FCF Ratio-6.86

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€28.30

Price Target Upside62.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)-2.27

Revenue Forecast (FY)€52.28M

Bulls Say, Bears Say

Bulls Say

Capitalization And Commercial ReadinessAnalyst notes that substantial cash reserves and established commercial launch readiness for the lead program provide financial runway to support an initial market entry and follow‑on product launches.

Clinical Efficacy And BiomarkersAnalyst highlights that tividenofusp alfa produced large, sustained reductions in multiple cerebrospinal and urine heparan sulfate biomarkers alongside reductions in neurofilament light, supporting potential for accelerated approval and clinical differentiation from current therapy.

Platform Delivery TechnologyAnalyst emphasizes that the Enzyme Transport Vehicle with transferrin receptor shuttling enables delivery to brain and muscle, reducing genomic safety concerns tied to viral vectors and expanding treatment reach across lysosomal disorders.

Bears Say

Execution And Market PressureAnalyst cautions that upcoming regulatory decisions, the need for successful confirmatory trials, and ongoing biotech sector macroeconomic pressure could drive share volatility and affect long‑term commercial prospects.

Regulatory Evidence RiskAnalyst warns that reliance on open‑label, nonrandomized clinical data increases approval uncertainty and makes regulatory decisions and confirmatory trial outcomes critical execution risks.

Safety And Preclinical SignalsAnalyst points to infusion‑related reactions as a recurrent safety issue and highlights a clinical hold linked to preclinical hypersensitivity signals that may require amended dosing and enhanced monitoring.

Denali Therapeutics News

Denali Therapeutics price target raised to $36 from $32 at BTIG

BTIG raised the firm’s price target on Denali Therapeutics (DNLI) to $36 from $32 and keeps a Buy...

2d ago

DNLI

Denali Therapeutics price target lowered to $34 from $37 at Stifel

Stifel analyst Paul Matteis lowered the firm’s price target on Denali Therapeutics (DNLI) to $34 from $37 and...

5d ago

DNLI

Denali Therapeutics reports Q4 EPS (73c), consensus (75c)

“In 2025, we made meaningful progress toward delivering urgently needed treatment options for people living with neurodegenerative diseases...

5d ago

DNLI

Denali Therapeutics initiated with a Peer Perform at Wolfe Research

Wolfe Research analyst Rudy Li initiated coverage of Denali Therapeutics (DNLI) with a Peer Perform rating and no...

8d ago

DNLI

Denali Therapeutics: Underappreciated Hunter Syndrome Launch and 2026 CNS Pipeline Catalysts Support Buy Rating

William Blair analyst Myles Minter has reiterated their bullish stance on DNLI stock, giving a Buy rating yesterday....

5d ago

DNLI

Denali Therapeutics: Differentiated Hunter Syndrome Strategy and Non-Viral Platform Support Buy Rating and Long-Term Franchise Upside

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Denali Therapeutics, with...

20d ago

DNLI

Denali Therapeutics: Strengthening LSD Clinical Profile and Attractive Risk‑Reward Support Buy Rating

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Denali Therapeutics. The associated...

26d ago

DNLI

Denali Therapeutics Advances New Early-Stage Alzheimer’s Drug Into Phase 1b Testing

Denali Therapeutics ($DNLI) announced an update on their ongoing clinical study. Study Overview Denali Therapeutics is launching a...

2M ago

DNLI

Denali Therapeutics price target raised to $40 from $32 at Morgan Stanley

Morgan Stanley analyst Sean Laaman raised the firm’s price target on Denali Therapeutics (DNLI) to $40 from $32...

2M ago

DNLI

Denali Therapeutics assumed with a Buy at UBS

UBS assumed coverage of Denali Therapeutics (DNLI) with a Buy rating and a price target of $25, up...

2M ago

DNLI

Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision

Denali Therapeutics ( ($DNLI) ) has provided an update. On January 6, 2026, Denali Therapeutics outlined its key...

2M ago

DNLI

Denali Therapeutics announces key milestones, priorities for 2026

Denali Therapeutics (DNLI) announced key anticipated milestones and priorities for 2026 across its portfolio of investigational therapies for...

2M ago

DNLI

Denali Therapeutics announces publication of Phase 1/2 study of DNL310

Denali Therapeutics (DNLI) announced the publication of results from the open-label Phase 1/2 clinical trial of its investigational,...

2M ago

DNLI

Denali Therapeutics price target lowered to $30 from $31 at Wedbush

Wedbush analyst Laura Chico lowered the firm’s price target on Denali Therapeutics (DNLI) to $30 from $31 and...

3M ago

DNLI

4DN FAQ

What was Denali Therapeutics’s price range in the past 12 months?

Denali Therapeutics lowest stock price was €10.17 and its highest was €19.23 in the past 12 months.

What is Denali Therapeutics’s market cap?

Denali Therapeutics’s market cap is €2.85B.

When is Denali Therapeutics’s upcoming earnings report date?

Denali Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 69 days.

How were Denali Therapeutics’s earnings last quarter?

Denali Therapeutics released its earnings results on Feb 26, 2026. The company reported -€0.619 earnings per share for the quarter, beating the consensus estimate of -€0.625 by €0.006.

Is Denali Therapeutics overvalued?

According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Denali Therapeutics pay dividends?

Denali Therapeutics does not currently pay dividends.

What is Denali Therapeutics’s EPS estimate?

Denali Therapeutics’s EPS estimate is -0.55.

How many shares outstanding does Denali Therapeutics have?

Denali Therapeutics has 158,591,490 shares outstanding.

What happened to Denali Therapeutics’s price movement after its last earnings report?

Denali Therapeutics reported an EPS of -€0.619 in its last earnings report, beating expectations of -€0.625. Following the earnings report the stock price went down -4.279%.

Which hedge fund is a major shareholder of Denali Therapeutics?

Currently, no hedge funds are holding shares in DE:4DN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Denali Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-45.69%

Trailing 12-Months

Asset Growth

-16.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics (4DN) Earnings & Revenues

Historic Earnings Reports

4DN Stock 12 Month Forecast

Average Price Target

€28.30

▲(62.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","16":"€16","22":"€22","28":"€28","34":"€34"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33.848164,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€33.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.297065104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€28.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.1551025,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.16</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,16,22,28,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.425,18.688320307692308,19.951640615384616,21.214960923076923,22.47828123076923,23.741601538461538,25.004921846153845,26.268242153846153,27.53156246153846,28.794882769230767,30.058203076923075,31.321523384615382,32.584843692307686,{"y":33.848164,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.425,18.261312700307695,19.097625400615385,19.93393810092308,20.77025080123077,21.606563501538464,22.442876201846154,23.279188902153848,24.11550160246154,24.951814302769233,25.788127003076923,26.624439703384617,27.46075240369231,{"y":28.297065104,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.425,17.711930961538464,17.998861923076923,18.285792884615386,18.572723846153846,18.85965480769231,19.14658576923077,19.43351673076923,19.720447692307694,20.007378653846153,20.294309615384616,20.58124057692308,20.86817153846154,{"y":21.1551025,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.515,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.945,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.115,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.16,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.01,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.425,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >